Johnson & Johnson
VerifiedOnline/Digital
t Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.
Every day, our more than 140,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity. Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | Dutch, English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesWhat you need to know about Johnson & Johnson’s second-quarter 2026 earnings report
This morning, Johnson & Johnson shared its second-quarter 2026 earnings report. Since its founding in 1886, the company has been committed to innovation—today, approximately 140,000 employees across the globe work to deliver solutions for patients around the world to help profoundly impact health for humanity. “Our second-quarter performance underscores the breadth and depth of Johnson & Johnson’s portfolio,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson.
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
New Brunswick, NJ (July 15, 2026) – Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything.
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
New Brunswick, N.J. (July 15, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson.
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Irvine, CA – July 8, 2026 – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single catheter.i “The FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform is another important milestone in what has been an incredible...
“We are in a golden age of cataract surgery”
1. From restoring sight to customizing vision with the intraocular lens From restoring sight to customizing vision with the intraocular lens British ophthalmologist Sir Harold Ridley created the first IOL in 1949, after observing that World War II pilots could tolerate small pieces of acrylic plastic that entered their eyes during combat. His invention was hailed as revolutionary, but it did have a drawback: The lens was monofocal.
DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer
RAYNHAM, Mass. (June 29, 2026) – DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced the appointment of Christina Zamarro as Chief Financial Officer, DePuy Synthes, effective July 13, 2026. Zamarro brings over 25 years of financial leadership experience serving in multitude of roles across treasury, investor relations, FP&A and accounting.
Johnson & Johnson presents new IMAAVY ® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
GENEVA, SWITZERLAND (June 26, 2026) – Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY® (nipocalimab-aahu) throughout clinically relevant points in the generalized myasthenia gravis (gMG) treatment journey.
CHMP recommendation advances Johnson & Johnson’s TECVAYLI ® ▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
BEERSE, BELGIUM (June 26, 2026) – Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of an indication extension of TECVAYLI® (teclistamab) in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
Johnson & Johnson Begins Enrollment in Pivotal Studies Evaluating First-of-its-Kind Carotid IVL Platform
SANTA CLARA, Calif. – June 25, 2026 – Johnson & Johnson announced today the initiation of its SKYWARD investigational device exemption (IDE) clinical program evaluating the novel ShockwaveSkyRunner Carotid Intravascular Lithotripsy (IVL) Systemi for the treatment of calcified carotid arteries prior to stenting.
Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Irvine, CA – 25 June, 2026 – Johnson & Johnson today announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe, expanding physician access to a dual-energy catheter ablation solution designed for personalized care across workflows, anatomies and procedural strategies.i The platform combines the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, an irrigated contact-force sensing catheter, with the TRUPULSE Generator to enable delivery of both...